
Integration of Biomarkers, MRI and PSMA PET Imaging Into the Management of Prostate Cancer Webcast (2025)
Integration of Biomarkers, MRI and PSMA PET Imaging Into the Management of Prostate Cancer is a 2-hour webcast featuring a multidisciplinary faculty, including a urologist, medical oncologist, and radiologist, each lending their expertise and unique perspective. Faculty will explore recent advances in biomarkers and molecular imaging technologies, focusing on their role in prostate cancer staging and treatment monitoring. Participants will learn the clinical scenarios in which to apply PSMA PET/CT to identify the localization and extent of locoregional or systemic metastatic disease, recognize its limitations, and integrate findings into individualized treatment strategies. This webcast will also address patient identification for radiorecurrent and organ-confined prostate cancer.
ACKNOWLEDGEMENTS
Support provided by independent educational grants from:
- Blue Earth Diagnostics, Inc.
- Lantheus Medical Imaging
- Novartis Pharmaceuticals Corporation
Target Audience
- Urologists
- APPs
- Residents
- Fellows
- Young Urologists
Learning Objectives
At the conclusion of this CME activity, participants will be able to:
- Evaluate recent advances in biomarkers and molecular imaging technologies and their role in improving the accuracy of prostate cancer staging, and treatment monitoring.
- Identify the clinical scenario in which PSMA PET/CT is most helpful to identify the localization and extent of locoregional or systemic metastatic disease.
- Identify the pitfalls of false-positive and false-negative PSMA PET/CT findings.
- Apply the findings of PSMA PET/CT for the best individual therapeutic approach.
- Identify patients with radiorecurrent organ-confined prostate cancer.
Welcome
Adam S. Kibel, MD
Beyond Sensitivity and Specificity with PSMA PET Imaging: Emerging Biomarkers
Steven Rowe, MD
MRI and Biomarkers for Evaluation
Rob Reiter, MD
Practical Applications of Using PET/MRI/Biomarkers for Management
Evan Yu, MD
Clinical Cases
All Faculty
Name | Company Name | Relationship Type | End Date |
Kibel, Adam S. | Janssen | Scientific Study or Trial | Current |
Bristol-Myers Squibb | Other-Data Safety Monitoring Board | 04/14/2025 | |
Cellvax | Consultant or Advisor | 04/14/2025 | |
Reiter, Robert Evan | No relevant financial relationships to disclose | ||
Rowe, Steven Patrick | Lantheus | Other-Speaker Bureau Member | Current |
Yu, Evan Y. | Merck Sharp & Dohme Corp | Consultant or Advisor | Current |
Lantheus | Scientific Study or Trial | Current | |
Bayer | Consultant or Advisor | Current | |
Astrazeneca | Consultant or Advisor | 03/04/2025 | |
Tolmar | Consultant or Advisor | 02/14/2025 | |
Johnson & Johnson | Consultant or Advisor | 03/21/2025 |
EDUCATION COUNCIL DISCLOSURE
Education Council Disclosures_June 2024.pdf
COI REVIEW WORK GROUP DISCLOSURES
COI Review Workgroup Disclosures_June 2024.pdf
AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.
AUA ACCREDITATION INFORMATION
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by taking the pretest, viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.
Estimated time to complete this activity: 2.00 hours
Release Date: May, 2025
Expiration Date: May, 2026
ACCREDITATION:
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION:
The American Urological Association designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
OTHER LEARNERS:
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual’s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.
MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification relevant financial relationships that result in of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
AUA PARTICIPANT INFORMATION & POLICIES
DISCLAIMER:
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
REPRODUCTION PERMISSION:
Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
Available Credit
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation